Dudediligence.

Relay Therapeutics, Inc

RLAYNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24$7.7MMar ’25$677,000Jun ’25$0.00Sep ’25$7.0MDec ’25$3.0MMar ’26$350,000Jun ’26
Net income, by quarter
−$88.1MSep ’24−$76.0MDec ’24−$77.1MMar ’25−$70.4MJun ’25−$74.1MSep ’25−$54.9MDec ’25−$73.3MMar ’26−$83.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$3.0M$1.4M$25.5M$10.0M$15.4M
Operating income−$364.7M−$299.3M−$373.0M−$372.5M−$302.7M
Net income−$363.9M−$290.5M−$342.0M−$337.7M−$276.5M
Operating cash flow−$74.4M−$229.5M−$300.3M−$249.1M−$235.5M
Free cash flow−$77.9M−$238.6M−$304.4M−$251.1M−$235.9M
Cash$280.1M$151.8M$143.7M$124.3M$84.0M
Shares outstanding108.2M121.1M127.5M167.8M173.9M